Form D · Other
Vor Biopharma Inc.
Cambridge, MA · CIK 0001817229
Offering snapshot reported Jul 10, 2020 · SEC filing
- Reported sold
- $110M Offering amount: $110M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 10, 2020 | Initial | $110,124,989 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370729
Source: Form D, filed Jul 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Ang | Director, Executive |
| Nathan Jorgensen | Executive |
| Sven Lundberg | Director |
| Amy Mendel | Executive |
| Kush Parmar | Director |
| Joshua Resnick | Director |
Issuer details
Industry: Other (See others in industry)
Address:
100 Cambridgepark Drive Suite 400
Cambridge, MA, 02140
Cambridge, MA, 02140